Bradner James E. 4

What Happened

• James E. Bradner, Executive Vice President, Research & Development at Amgen (AMGN), received equity awards on 2026-05-05: a derivative equity grant of 21,773 units valued at $329.59 each (~$7,176,163) and 3,337 restricted stock units (RSUs). On 2026-05-06, 407 shares were surrendered/disposed at $329.59 per share to satisfy tax withholding obligations (proceeds ≈ $134,143). The 407-share disposition is recorded as tax withholding (routine), not an open-market sale.

Key Details

• Transaction dates and values:
  • 2026-05-05: Award/grant — 21,773 derivative units @ $329.59 each = $7,176,163 (derivative award)
  • 2026-05-05: Award/grant — 3,337 RSUs @ $0.00 (reported as grant)
  • 2026-05-06: Tax withholding (F) — 407 shares disposed @ $329.59 = $134,143
• Shares owned after transaction: Not specified in the filing.
• Relevant footnotes from the filing:
  • F1: RSUs vest in four equal annual installments (25% each) beginning 5/5/2027; vested RSUs paid 1:1 in common stock.
  • F2: The award includes 1,332 Dividend Equivalents credited to unvested RSUs, paid in shares on vesting (plus cash for fractional shares).
  • F3: The derivative units include non-qualified stock options that vest/exercise in four equal annual installments starting 5/5/2027.
• Filing timeliness: Report filed 2026-05-07 for transactions on 2026-05-05/05-06 — appears to be a timely Form 4 filing.

Context

• The large grants are typical long-term incentive awards (RSUs and stock options) that vest over multiple years; they are intended for retention and compensation rather than immediate market bets.
• The 407-share disposition is a tax-withholding action (code F), a routine administrative step when equity awards are granted; it should not be interpreted as a discretionary sale of stock.
• For options/derivative awards, note these grants vest beginning 5/5/2027 in four equal annual installments — the awards are not immediately exercisable.